The naturally occurring polyamines are found in all living cells, where they fulfil a number of critical functions in relation to cell growth. The quest to identify these functions has been the subject of five independent colloquia hosted by the Biochemical Society and today still occupies several hundred scientists across Europe, the U.S.A. and Japan.
Despite having been isolated more than 300 years ago, the research interest in the polyamines only took off in the 1970s. Since then, many thousands of papers have shown their involvement in all aspects of cellular metabolism, including cell growth and differentiation, DNA replication and repair, RNA synthesis and processing, and protein synthesis and metabolism (for a review, see [1] ).
The term 'polyamines' generally, although not strictly correctly, refers to spermine (a tetra-amine), spermidine (a tri-amine) and putrescine (a diamine): Other oligoamines and diamines, such as thermine and cadaverine, also occur naturally, but are not included usually within the general term 'polyamines'. At physiological pH, the polyamines are positively charged, and some of their actions within cells are a direct result of chargecharge interactions. For example, polyamines bind to and facilitate the condensation of DNA by neutralizing the negative charges on the phosphate backbone [1] . It is however naïve to think that all the functions of the polyamines could be due to charge interactions. The complexity of the synthesis and catabolism of the polyamines, involving at least seven individual enzyme reactions, and the intricate control over homoeostasis argues strongly that these compounds are critical for cell viability and growth. The fact that they are found in almost every living cell supports their vital role in metabolism. In recent years, as improved technology has enabled the unravelling of more complex regulatory mechanisms within cells, novel features have been identified in polyamine metabolic processes. For example, the +1 frameshift induced by the polyamines to produce antizyme that then targets ornithine decarboxylase, the first step in the biosynthetic pathway, for degradation by the 26 S proteasome was a unique finding [2] . The regulation of S-adenosylmethionine decarboxylase expression in plants by the tiny upstream open reading frame (ORF) and the small upstream ORF [3] is another interesting example of the multiple levels of regulation of polyamine production in cells.
As the Biochemical Society changes the profile of its meetings to more focused one-day Symposia, it seems appropriate to look back over the association of the Society with those of us working in the polyamine field. This was the fifth colloquium on polyamines held in the U.K. in association with the Society. The first meeting, entitled 'Polyamines', was held in Stirling in 1985 as a part of the 610th Biochemical Society Meeting. It was a Society Special Colloquium, and was organized by David Morgan and Terry Smith on behalf of both the Biochemical Society and the British Polyamine Group. The focus of the meeting was polyamine metabolism in slime moulds, bacteria, plants, viruses and in mammalian cells [4] , and there were 12 presentations (eight speakers and four posters). At each of the subsequent meetings (635th Meeting in Aberdeen, 1990 [5] ; 651st Meeting in Lancaster, 1994 [6] ; and 666th Meeting in Sheffield in 1998 [7] ), the number of participants increased steadily with the latest meeting in London (678th Meeting) attracting 16 invited speakers from across Europe, the U.S.A. and Japan, 17 posters and over 65 participants. Each colloquium has addressed the progress in understanding the relationship between polyamines and essentially disease in man. Two areas in particular have remained topical over time, namely the role of polyamines in cancer and the use of inhibitors of polyamine metabolism as trypanocidal agents. In the cancer field, the focus has moved from assessing the utility of single enzyme inhibitors, such as α-difluoromethylornithine ('DFMO'), as anti-cancer agents to the potential use of polyamine analogues that target more than one reaction in the polyamine metabolic pathway, and hence provide potentially greater polyamine depletion, and consequently greater antiproliferative effects. In addition, polyamine inhibitors are being evaluated currently as possible chemopreventative agents. In the treatment of parasitic disease, polyamine antimetabolites continue to be effective agents against a range of parasites. Looking back over these last 17 or so years, our basic understanding of polyamine biochemistry has progressed enormously from investigating simple organisms such as bacteria to producing novel inhibitors that have potential to cure parasitic diseases and treat cancers. It is the sheer complexity of the regulatory systems controlling polyamine homoeostasis that excites polyamine researchers and keeps us focused on this productive area of research.
